Finorify

RPRX

Royalty Pharma

$58.49+3.86%

Price

RPRX daily closing price
Market cap
$25.16 billion
P/E (TTM)
29.84
EV/EBITDA
28.17
Volume
2.8M
Sector
Healthcare

Royalty Pharma (RPRX) last closed at $58.49, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for RPRX, covered for search and blurred for visitors.

Performance

  • 1D-0.16%
  • 5D+5.36%
  • 1M+6.20%
  • 3M+5.30%
  • 6M+25.00%
  • 1Y+69.67%
  • 5Y+73.46%

Financials

RPRX revenueQ3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26

Over the latest four reported periods ending March 31, 2026, Royalty Pharma reported revenue of $2.39 billion.

The prior window totaled $2.21 billion, so the latest window is higher than that stretch.

Operating cash flow in the latest window was $2.38 billion.

Free cash flow in the latest window was $2.38 billion.

These amounts are taken from Royalty Pharma's SEC filings and are a snapshot as of July 24, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.

A few ratios from those statements: Profitability: ROA 1.5% (39 of 100). Cash generation: FCF margin 99.8% (100 of 100). Net margin: 46.7% (100 of 100). Liquidity: Current 2.66× (100 of 100).

Cash Flow

RPRX free cash flowQ3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26

Margins

RPRX operating margin

Valuation

P/E (TTM)
29.84
P/S (TTM)
10.70
EV/EBITDA
28.17

Insights

Finorify has not written notes for RPRX in this snapshot.

Read the live analysis in Finorify

Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.

Open RPRX in Finorify